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IN recent years the monitoring of plasma drug levels carried out with a view to
relating these with the clinical response produced by drugs has emerged as one ofthe
expanding areas of medicine. There are now a number of examples of drugs where
this approach has provided a basis for the appropriate adjustment of the dosage
given and contributed to the understanding of drug toxicity.
Prednisolone ('A-cortisol), a synthetic glucocorticoid is widely used as an
immunosuppressive in renal transplant patients. The amount given is between
50-300 mg/daily for the first few days after transplantation. This is gradually
reduced over the first three months to a maintenance dose of 10-20 mg/day. The
details of the schedule may vary depending on the local preference. Little is known
about the circulating drug concentration achieved in these patients after steroid
therapy and whether any derangement of the plasma drug kinetics may be
implicated in rejection episodes or in the exaggerated action of corticoids observed
in some patients.
MEASUREMENT OF PREDNISOLONE
The analytical techniques that have been applied to the measurement of
prednisolone include fluorimetry/colorimetry, gas chromatography, competitive
protein-binding assay, radioimmunoassay, high performanceliquidchromatography.
Among the procedures that have been reported for such determination in body
fluids, those based on competitive protein building' and radioimmunoassay (RIA)2,
have been most widely used. One limitation ofthe former is that prednisolone has to
be isolated by a chromatographic step in order to eliminate the interference from
cortisol and other steroids. The RIA on the other hand allows high sample
throughput and, from various other practical considerations, is the method of
choice. The more recent use4,s of high performance liquid chromatography (HPLC)
with UV-detection system (254, 239 nm) for the determination of prednisolone
although less sensitive that RIA, looks promising. The important advantage of this
over other procedures is that cortisol and prednisolone (and possibly its metabolites)
may be measured simultaneously.
Radioimmunoassay ofprednisolone
The method developed at the University of Surrey is as follows. The antiserum
was raised in sheep against prednisolone-21-hemisuccinate conjugated to bovine
serum albumin and used at an initial dilution of 1:2,250. The cross-reactivity of the
antiserum with various steroids is given in Table 1. The sample (0.2-1ml) is extracted
43TABLE 1
Cross-reactivity of various steroids with prednisolone antiserum in absence of
prednisolone
Cross-reactivity (%)
Prednisolone 100
Prednisone 11.1
20-Dihydroprednisolone 20.6
Cortisol 3.9
Cortisone 2.8
Progesterone 0.6
Testosterone 0.1
Cholesterol 0.1
with ethyl acetate (3 ml x 2), the extracts pooled and dried by evaporation at 400
under a stream of nitrogen. The residue is reconstituted in 0.5 ml and O.iM
phosphate buffer, pH 7.4 and aliquots (0.1 ml, either neat or appropriately diluted)
analysed for prednisolone by RIA. Detailed information on the RIA has been
lodged with the Editor. The sensitivity of the assay is 1 ng/ml. Replicate assays
carried out on pooled normal human plasma to which known amounts of
prednisolone was added gave coefficient of variation 3.6-5.9/o within batch and
5.1-7.3 between batch.
HUMAN STUDIES
Prednisolone absorption
After ingestion of plain prednisolone tablets orally, peak plasma drug levels are
achieved, according to most reports, within the first hour and the plasma half-life of
prednisolone is 2.5 -3.5h.6.8'9 10, 11 Most published studies on plasma prednisolone
levels were carried out with 10-30 mg doses. The values quoted for the same doses,
however, vary between reports and this, at least in part, may be attributed to
differences in metholology used for prednisolone and in the experimental protocol.
Another feature of prednisolone bioavailability which appears to be prominent is
inter-individual variation even in healthy subjects, as illustrated in Fig. 1. After an
oral dose of 10 mg (plain tablets) plasma peak prednisolone levels in these six
subjects ranged between 165 and 260 ng/ml with a mean value of 202 + S.D. 34.6.
The amount of unchanged prednisolone isolated from 24h urine by thin layer
chromatography (polythene-backed silica gel plates; dichloromethane/ethanol/
water, 150:10:1, v/v) followed by RIA varied between 11.1 and 19.4% of the
administered dose (mean value 13.6 + S.D. 3.2).
From the available data it is hardly possible to construct a useful dose-plasma
prednisolone level curve for reasons mentioned before. Some examples ofthe values
collected from literature2' 4. 7-l are shown in Table 2.
Enteric-coated tablets
There have been some conflicting reports on the bioavailability of enteric-coated
prednisolone compared with that of the plain tablets. According to Lee et al., 6 the
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TABLE 2
Some reported2 values ofplasmaprednisolone level
afterplain tablets given by mouth
Dose (mg) Plasma prednisolone (ng/ml)
10 248
10 227
10* 250
10 246
15 139
20 375
20 185
50 500
50* 807
60 684
90 1,343
* Prednisone given.
45pattern of absorption and plasma prednisolone levels depend on the formulation of
the enteric coating. They concluded that the bioavailability ofthe more recent CAP-
based preparation, unlike the previously used shellac-based tablets, is consistent and
similar to that of plain prednisolone. They also found that the presence of food in
the stomach at the time of the drug ingestion (20 mg) did not alter the absorption of
CAP-enteric-coated tablets (Fig. 2).
FIGURE 2
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Meanplasmaprednisolone concentrations afterenteric-coated tablets tofasted(Z)
and non-fastedsubjects (U). Dose range 15-22.2 mg. (Lee et al)16
Renal transplant recipients-Study I
Plasma prednisolone levels were monitored in 8 renal transplant patients, 5 men
and 3 women within three weeks after transplantation.3 No restriction was imposed
on their food and drink intake and they received by mouth their respective doses of
CAP-based enteric-coated prednisolone tablets. Some of the findings are given in
Tables 3, 4 and 5. These show a gross variation in the rate of appearance of
prednisolone in the blood and peak values achieved irrespective of the dosage used.
After the same dose given to different patients or to the same patients on two
separate occasions, there was a difference in the time required to reach peak plasma
prednisolone concentrations and, more strikingly, in the magnitude of the values
obtained.
Breakfast taken before dosing resulted in adelay of7-10 hours before peak values
were reached. Furthermore, fasting before taking prednisolone produced up to
eightfold higher peak concentrations after 175 and 150 mgdoses, but not after 20 or
50 mg doses.
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Plasmaprednisolone levels (ng/ml) after oral doses in renal transplantpatients
Time (h) Dose (mg) andplasma prednisolone (ng/ml)
200 mg 200 mg 175 mg 175 mg
0 67 0 630 400
0.5 900 90 500 325
1 1,067 100 490 250
2 900 3,000 1,470 188
4 1,017 3,350 4,700 163
8 1,267 2,550 3,350 423
TABLE 4
Plasmaprednisolone levels (ng/ml) after oral doses in renal transplantpatients
Time (h) Dose (mg) andplasma prednisolone (ng/ml)
175 mg 150 mg 125 mg 100 mg
I II
0 955 375 933 70
0.5 295 1,067 450 1,070
1 898 227 1,333 300 570
2 852 841 1,367 250 660
4 943 1,875 1,400 613 1,300
8 1,057 716 1,017 688 670
TABLE 5
Plasmaprednisolone (ng/ml) concentrations in renal transplantpatients
after an oral dose
Time (h) Dose 125 mg Dose 100 ing
I II* I* II
0 267 133 160 70
0.5 183 67 170 1,070
1 117 550 240 570
2 183 717 201 660
4 900 1,533 350 1,300
8 917 833 1,350 670
Drug was measured on two consecutive days. *: Haemodialysis was carried out.
47Renal transplant recipients-Study 2
Ten patients with stable renal function two years after transplantation who were
receiving prednisolone orally (2 x 5 mg enteric-coated tablets) as the only immuno-
suppressive treatment were included in this investigation.'7 The prednisolone dose
was reduced by 1 mg at monthly intervals by replacing one of the 5 mg tablets with
the appropriate number of 1 mg tablets. After the patient had been on a dose for one
week, plasma drug levels were determined at 1, 3 and 6h following the daily dose.
Some of these results are given in Table 6.
TABLE 6
Patients with renal transplant-Stepwise reduction ofprednisolone dose'7
Creatinine Lowest Plasma
Case clearance at prednisolone prednisolone
Patient No. start (ml/min) dose (mg/day) (ng/ml) at 3 h.
10mg 8mg
Non-rejection 1 72.7 1 88 96
2 61.5 1 11 91
3 64.0 5 86 78
Rejection 4 61.0 3 140 5
5 72.8 6 0 49
6 79.6 5 116 92
7 80.0 4 91 91
8 80.0 2 0 97
Others 9 53.0 6 192 15
10 86.6 5 93 82
The patients (1, 2 & 3) in the non-rejection group remained well at daily doses of 1, 1
& 5 mg respectively. The reduction of prednisolone dose in patients 9 and 10 had to
be stopped because of acute pyelonephritis and symptoms of cortisol deficiency
respectively. The plasma prednisolone values obtained after 7-10 mg oral doses were
not proportional to the size of the dose; in this respect, no clear and consistent
pattern of differences emerged between the groups or between individual patients.
On some occasions (Case Nos. 2, 5 & 8, 10 mg; Case No. 4, 8 mg) prednisolone was
hardly detectable in plasma.
CONCLUSION
With the availability of RIA methods for prednisolone and other synthetic
corticoids it should now be possible to examine critically the various aspects of the
use of immunosuppressive steroids in renal transplant patients. It is clear from the
studies presented here that the continued use of enteric-coated prednisolone tablets,
especially when a large number of tablets make up the required dose, needs careful
appraisal. Considerations have also got to begiven to the effect of food on intestinal
absorption and the patient's gastrointestinal activity which may be contributory
factors in the gross variation in plasma drug levels observed in the transplant
48patients. Low concentrations of prednisolone in plasma noted in some instances
(Study 1) might be potentially hazardous, possibly favouring graft rejection.
Whether the concept of a standard 'minimum threshold dose' compatible with
graft survival can be generally applicable remains to be established. The preliminary
data presented here provide a useful basis for. future more elaborate studies of
patients who sustain stable renal function with low maintenance doses of
prednisolone. Any progress made in understanding the 'therapeutically effective'
plasma prednisolone concentration, determined preferably by using plain tablets
throughout, should be an important step forward towards adjusting dosage
according to individual capacity to handle prednisolone. Such information may also
prove to be a useful adjunct to the assessment of the undesirable side effects of
corticoids and chrono-biological evaluation of the standard protocol used for
steroid therapy.
I wish to thank the Arthritis & Rheumatism Council, Great Britain for supporting the radioimmunoassay
work on synthetic corticosteroids.
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